Radioligand therapy (RLT) used to treat cardiac metastasis of pancreatic neuroendocrine tumor

Kieran J Ved; Arjun Bhatt; Aidan M Burke; Michael C Larkins; Dishita Pandya; Constantin B Marcu

doi:10.1002/ccr3.8622

Radioligand therapy (RLT) used to treat cardiac metastasis of pancreatic neuroendocrine tumor

Clin Case Rep. 2024 Mar 5;12(3):e8622. doi: 10.1002/ccr3.8622. eCollection 2024 Mar.

Authors

Kieran J Ved¹, Arjun Bhatt¹, Aidan M Burke², Michael C Larkins¹, Dishita Pandya³, Constantin B Marcu³

Affiliations

¹ Brody School of Medicine, East Carolina University Greenville North Carolina USA.
² Department of Radiation Oncology, Brody School of Medicine East Carolina University Greenville North Carolina USA.
³ Department of Cardiovascular Sciences, Brody School of Medicine East Carolina University Greenville North Carolina USA.

Abstract

Radioligand Therapy (RLT) in the form of [177Lu] Lu-DOTA-TATE (Lutathera®) is a promising treatment for pancreatic neuroendocrine tumors (pNETs) with cardiac metastasis. We present a patient treated with [177Lu] Lu-DOTA-TATE that showed shrinkage of metastasis after four treatments at 7.4 GBq every 8 weeks.

Keywords: Lutathera; cardiac metastases; neuroendocrine neoplasms (NENs); peptide receptor radiotherapy (PRRT); somatostatin receptor.

Publication types

Case Reports